Furthermore, patients with cardiomyopathy secondary to complement‐mediated TMA, including those with atypical HUS and those with known complement Factor H gene mutations or autoantibodies directed against Factor H, showed clinical response to eculizumab treatment with improvement in their cardiomyopathy [36]. Here, CFH is linked to hemolytic-uremic syndrome.